TaeJin Ahn
Research Subjects
TaeJin Ahn has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Eun Ji Song
Foretell My Health, Inc., 558 Handong-ro Buk-gu, Pohang 37554, Republic of Korea
3 shared publications - Eunyong Ahn
Foretell My Health, Inc., 558 Handong-ro Buk-gu, Pohang 37554, Republic of Korea
3 shared publications - Hyunjung Kim
Foretell My Health, Inc., 558 Handong-ro Buk-gu, Pohang 37554, Republic of Korea
3 shared publications - Kyung-Ah Hwang
Department of Genomic Strategy, Samkwang Labtree, Seoul 06740, Republic of Korea
3 shared publications - Sarah Kim
Foretell My Health, Inc., 558 Handong-ro Buk-gu, Pohang 37554, Republic of Korea
3 shared publications - Se Ik Kim
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
Foretell Ovary: A Blood-Based Ensemble Algorithm Integrating Tumor-Educated Platelet RNA and Routine Hematology for Non-Invasive Ovarian Cancer Screening
Background: Ovarian cancer is the most lethal gynecologic malignancy, and CA-125 has limited early-stage sensitivity. We developed and evaluated Foretell Ovary, an ensemble machine-learning classifier that integrates tumor-educated-platelet RNA markers and routine hematologic parameters for non-invasive ovarian cancer detection, and compared it head-to-head with CA-125. Methods: A multi-site prospective cohort study enrolled 460 South Korean participants (67 ovarian cancer, 15 borderline ovarian tumors, 197 benign gynecological conditions, and 181 asymptomatic controls) at six clinical sites between September 2024 and March 2026. The cohort was split into training (n = 279) and independent test (n = 181) sets under a pre-specified ACTB cycle threshold ≤ 28 per-protocol rule (test n = 169). The classifier blended a random forest and two calibrated logistic-regression sub-models built on eight platelet RNA markers, 24 complete blood count parameters, and 30 marker-by-hematology combination features. Performance was assessed at a pre-frozen cutoff of 0.44 and compared against CA-125 (35 U/mL cutoff) in a matched subset (n = 100). Results: Foretell Ovary achieved an area under the receiver operating characteristic curve (AUC) of 0.923, sensitivity of 87.5% (100.0% for Stage II–IV), specificity of 89.0%, and negative predictive value of 97.7% in the test set. In the matched subset, Foretell Ovary outperformed CA-125 on every metric (AUC 0.839 vs. 0.723; sensitivity 85.0% vs. 65.0%), with the largest gap in pre-menopausal participants (+25 percentage points in sensitivity). A three-tier risk-grading scheme retained no ovarian cancer in the low-risk grade. Conclusions: Foretell Ovary offers more accurate non-invasive detection of ovarian cancer than CA-125, particularly in pre-menopausal women, offering the flexibility to be used alone or combined with CA-125. Prospective validation studies are warranted.
Open AccessForetell Ovary: A Blood-Based Ensemble Algorithm Integrating Tumor-Educated Platelet RNA and Routine Hematology for Non-Invasive Ovarian Cancer Screening
Background: Ovarian cancer is the most lethal gynecologic malignancy, and CA-125 has limited early-stage sensitivity. We developed and evaluated Foretell Ovary, an ensemble machine-learning classifier that integrates tumor-educated-platelet RNA markers and routine hematologic parameters for non-invasive ovarian cancer detection, and compared it head-to-head with CA-125. Methods: A multi-site prospective cohort study enrolled 460 South Korean participants (67 ovarian cancer, 15 borderline ovarian tumors, 197 benign gynecological conditions, and 181 asymptomatic controls) at six clinical sites between September 2024 and March 2026. The cohort was split into training (n = 279) and independent test (n = 181) sets under a pre-specified ACTB cycle threshold ≤ 28 per-protocol rule (test n = 169). The classifier blended a random forest and two calibrated logistic-regression sub-models built on eight platelet RNA markers, 24 complete blood count parameters, and 30 marker-by-hematology combination features. Performance was assessed at a pre-frozen cutoff of 0.44 and compared against CA-125 (35 U/mL cutoff) in a matched subset (n = 100). Results: Foretell Ovary achieved an area under the receiver operating characteristic curve (AUC) of 0.923, sensitivity of 87.5% (100.0% for Stage II–IV), specificity of 89.0%, and negative predictive value of 97.7% in the test set. In the matched subset, Foretell Ovary outperformed CA-125 on every metric (AUC 0.839 vs. 0.723; sensitivity 85.0% vs. 65.0%), with the largest gap in pre-menopausal participants (+25 percentage points in sensitivity). A three-tier risk-grading scheme retained no ovarian cancer in the low-risk grade. Conclusions: Foretell Ovary offers more accurate non-invasive detection of ovarian cancer than CA-125, particularly in pre-menopausal women, offering the flexibility to be used alone or combined with CA-125. Prospective validation studies are warranted.
- Open Access
Innovative qPCR Algorithm Using Platelet-Derived RNA for High-Specificity and Cost-Effective Ovarian Cancer Detection
Background/Objectives: Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies, largely due to the challenges of early detection. While next-generation sequencing (NGS) has been explored for screening, its high cost limits large-scale implementation. To develop a more accessible diagnostic solution, we designed a qPCR-based algorithm optimized for early OC detection, with a focus on high-grade serous ovarian cancer (HGSOC), the most aggressive subtype. Methods: Peripheral blood samples from 19 ovarian cancer patients, 37 benign tumor patients, and 34 asymptomatic controls were analyzed using RNA sequencing to identify splice junction-based biomarkers with minimal expression in benign samples but elevated in OC. Results: A final panel of 10 markers was validated via qPCR, demonstrating strong agreement with sequencing data (R2 = 0.44–0.98). The classification algorithm achieved 94.1% sensitivity and 94.4% specificity (AUC = 0.933). Conclusions: By leveraging platelet RNA profiling, this approach offers high specificity, accessibility, and potential for early OC detection. Future studies will focus on expanding histologic diversity and refining biomarker panels to further enhance diagnostic performance.
Open AccessInnovative qPCR Algorithm Using Platelet-Derived RNA for High-Specificity and Cost-Effective Ovarian Cancer Detection
Background/Objectives: Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies, largely due to the challenges of early detection. While next-generation sequencing (NGS) has been explored for screening, its high cost limits large-scale implementation. To develop a more accessible diagnostic solution, we designed a qPCR-based algorithm optimized for early OC detection, with a focus on high-grade serous ovarian cancer (HGSOC), the most aggressive subtype. Methods: Peripheral blood samples from 19 ovarian cancer patients, 37 benign tumor patients, and 34 asymptomatic controls were analyzed using RNA sequencing to identify splice junction-based biomarkers with minimal expression in benign samples but elevated in OC. Results: A final panel of 10 markers was validated via qPCR, demonstrating strong agreement with sequencing data (R2 = 0.44–0.98). The classification algorithm achieved 94.1% sensitivity and 94.4% specificity (AUC = 0.933). Conclusions: By leveraging platelet RNA profiling, this approach offers high specificity, accessibility, and potential for early OC detection. Future studies will focus on expanding histologic diversity and refining biomarker panels to further enhance diagnostic performance.